2-[4-(dimethylamino)phenyl]-N-methoxy-N-methylacetamide | 848170-26-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[4-(dimethylamino)phenyl]-N-methoxy-N-methylacetamide
• 英文别名: 2-(4-Dimethylamino-phenyl)-N-methoxy-N-methyl-acetamide
• CAS: 848170-26-3
• 化学式: C₁₂H₁₈N₂O₂
• 分子量: 222.287
• InChiKey: QYMBEIGVEBSSJE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-[4-(dimethylamino)phenyl]-N-methoxy-N-methylacetamide 在 哌啶 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 2.5h， 生成 1-(3,4-Dichloro-phenyl)-2-(4-dimethylamino-phenyl)-propenone
  参考文献：
  名称：

  Discovery of non-steroidal mifepristone mimetics: Pyrazoline-based PR antagonists

  摘要：

  Mifepristone is a non-selective antagonist of 3-oxosteroid receptors with both abortifacient and anti-endometriotic activities. Non-steroidal mimetics of mifepristone and progesterone are important templates for modulation of the progesterone receptor (PR). For our PR program, we sought an unexplored, synthetically accessible non-steroidal mimetic of mifepristone, suitable for parallel synthesis of analogues. Docking of compounds into a PR homology model identified 4-substituted pyrazolines, which, when synthesized and tested, exhibited functional antagonism of PR. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.05.001
• 作为产物：
  描述：

  4-(二甲氨基)苯乙酸 在 吡啶 、 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 2-[4-(dimethylamino)phenyl]-N-methoxy-N-methylacetamide
  参考文献：
  名称：

  Discovery of non-steroidal mifepristone mimetics: Pyrazoline-based PR antagonists

  摘要：

  Mifepristone is a non-selective antagonist of 3-oxosteroid receptors with both abortifacient and anti-endometriotic activities. Non-steroidal mimetics of mifepristone and progesterone are important templates for modulation of the progesterone receptor (PR). For our PR program, we sought an unexplored, synthetically accessible non-steroidal mimetic of mifepristone, suitable for parallel synthesis of analogues. Docking of compounds into a PR homology model identified 4-substituted pyrazolines, which, when synthesized and tested, exhibited functional antagonism of PR. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.05.001

文献信息

• Synthesis, Structure−Activity Relationship, and Receptor Pharmacology of a New Series of Quinoline Derivatives Acting as Selective, Noncompetitive mGlu1 Antagonists
  作者：Dominique Mabire、Sophie Coupa、Christophe Adelinet、Alain Poncelet、Yvan Simonnet、Marc Venet、Ria Wouters、Anne S. J. Lesage、Ludy Van Beijsterveldt、François Bischoff

  DOI：10.1021/jm049499o

  日期：2005.3.1

  We describe the discovery and the structure-activity relationship of a new series of quinoline derivatives acting as selective and highly potent noncompetitive mGlu1 antagonists. We first identified cis-10 as a fairly potent mGlu1 antagonist (IC(50) = 20 nM) in a cell-based signal transduction assay on the rat mGlu1 receptor expressed in CHO-K1 cells, and then we were able to design and synthesize

  我们描述了发现和一系列新的喹啉衍生物作为选择性和高效非竞争性mGlu1拮抗剂的结构和活性之间的关系。我们首先基于CHO-K1细胞中表达的大鼠mGlu1受体的细胞信号转导试验，将cis-10鉴定为一种相当有效的mGlu1拮抗剂（IC（50）= 20 nM），然后我们能够进行设计和合成以化合物cis-64a为例，对大鼠和人mGlu1受体均具有高度有效的化合物，该化合物对人mGlu1受体的拮抗效力为0.5 nM。我们简要介绍并讨论了人肝微粒体中化合物的体外代谢稳定性。我们最终报告了我们的先导化合物cis-64a的药代动力学特性。
• [EN] NOVEL DIHYDROPYRIMIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS DIHYDROPYRIMIDINE-2(1H)-ONES EN TANT QU'INHIBITEURS DE LA S-NITROSOGLUTATHION RÉDUCTASE
  申请人：N30 PHARMACEUTICALS LLC

  公开号：WO2011038204A1

  公开（公告）日：2011-03-31

  The present invention is directed to novel dihydropyrimidin-2(1H)-one compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.

  本发明涉及一种新型二氢嘧啶-2(1H)-酮化合物，可用作S-亚硝基谷胱甘肽还原酶（GSNOR）抑制剂，包括这些化合物的药物组合物，以及制备和使用这些化合物的方法。
• FUSED RING HETEROCYCLE KINASE MODULATORS
  申请人：Arnold D. William

  公开号：US20070287711A1

  公开（公告）日：2007-12-13

  The present invention provides novel fused ring heterocycle kinase modulators and methods of using the novel fused ring heterocycle kinase modulators to treat diseases mediated by kinase activity.

  本发明提供了新型的融合环杂环激酶调节剂及其使用方法，用于治疗由激酶活性介导的疾病。
• Fused Ring Heterocycle Kinase Modulators
  申请人：Arnold William D.

  公开号：US20100036118A1

  公开（公告）日：2010-02-11

  The present invention provides novel fused ring heterocycle kinase modulators and methods of using the novel fused ring heterocycle kinase modulators to treat diseases mediated by kinase activity.

  本发明提供了新型融合环杂环激酶调节剂和使用这些新型融合环杂环激酶调节剂治疗由激酶活性介导的疾病的方法。
• Fused ring heterocycle kinase modulators
  申请人：SGX Pharmaceuticals, Inc.

  公开号：US08268994B2

  公开（公告）日：2012-09-18

  The present invention provides novel fused ring heterocycle kinase modulators and methods of using the novel fused ring heterocycle kinase modulators to treat diseases mediated by kinase activity.

  本发明提供了新型融合环杂环激酶调节剂以及使用这些新型融合环杂环激酶调节剂治疗由激酶活性介导的疾病的方法。